Thomas Goddemeier
Darmstadt, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
Journal: British journal of cancer
Published: April 07, 2023
Practical implementation of the partial ordering continual reassessment method in a Phase I combination-schedule dose-finding trial.
Journal: Statistics in medicine
Published: December 03, 2021
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 21, 2021
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Journal: NPJ breast cancer
Published: July 02, 2021
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Journal: Investigational new drugs
Published: March 05, 2014
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Journal: Investigational new drugs
Published: November 26, 2012
Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 07, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026